When to Discharge a Patient with Acute Decompensated HFpEF
Discharge the patient only after they have been hemodynamically stable, euvolemic, established on evidence-based oral medication, and maintained stable renal function for at least 24 hours. 1
Specific Discharge Criteria
Your patient must meet ALL of the following before discharge:
Hemodynamic Stability (Must be stable for ≥24 hours)
- Heart rate 60-120 bpm
- Systolic blood pressure ≥90 mmHg (ideally >115 mmHg for lower risk)
- SaO2 ≥90% on room air or minimal supplemental oxygen
- No evidence of organ hypoperfusion (normal mentation, adequate urine output)
- No signs of right heart failure with hypoperfusion 1
Euvolemia Achieved
- Resolution of pulmonary congestion (no rales, improved dyspnea)
- Resolution of peripheral edema
- Successfully transitioned from IV to oral diuretics for ≥24 hours 2
- Daily weights stable or trending down
- Accurate fluid balance chart showing net negative or neutral balance 1
Renal Function Stability
- Creatinine and electrolytes stable for ≥24 hours
- No worsening renal function with diuresis
- Daily monitoring of urea, creatinine, and electrolytes should show stability 1
Medication Optimization
- Established on appropriate oral medications for at least 24 hours
- For HFpEF specifically: Consider SGLT2 inhibitors, MRAs, and GLP-1 receptor agonists as disease-modifying therapies 3
- Medication reconciliation completed 2
Additional Prognostic Considerations
Pre-Discharge Risk Stratification
Measure natriuretic peptides before discharge - patients whose BNP/NT-proBNP concentrations fall during admission have lower cardiovascular mortality and readmission rates at 6 months 1.
- ANP (atrial natriuretic peptide) >113 pg/mL at discharge is associated with significantly higher risk of rehospitalization within 90 days in HFpEF patients 4
- ANP appears more predictive than BNP for early rehospitalization in HFpEF specifically 4
Common Pitfalls to Avoid
Premature discharge before 24-hour stability period: Even if the patient appears clinically improved, the 24-hour observation period on oral medications is critical to ensure sustained stability 1
Inadequate decongestion: Residual congestion at discharge is strongly associated with early readmission in HFpEF 5. Don't discharge with persistent edema, elevated JVP, or ongoing dyspnea.
Ignoring renal function trends: Worsening renal function during diuresis requires reassessment and stabilization before discharge 1
Missing high-risk features: Elevated discharge natriuretic peptides, particularly ANP >113 pg/mL, should prompt consideration of more intensive outpatient follow-up 4
Mandatory Discharge Planning
Before the patient leaves:
Provide comprehensive written discharge instructions covering: diet, medications (with emphasis on adherence), activity level, daily weight monitoring, and what to do if symptoms worsen 2
Schedule follow-up within 7 days with primary care provider 1, 6
Schedule cardiology follow-up within 2 weeks if feasible 1
Arrange telephone follow-up within 3 days of discharge 1
Enroll in disease management program or multidisciplinary heart failure service 1, 6
Clinical Context for HFpEF
The normal angiogram in your patient confirms non-ischemic etiology. HFpEF patients typically have multiple comorbidities (hypertension, diabetes, obesity, atrial fibrillation) that contribute to their decompensation 3. The preserved EF means traditional HFrEF therapies have limited evidence, though newer agents (SGLT2 inhibitors, MRAs) show benefit and should be initiated before discharge when hemodynamically stable 3.
The 24-hour stability requirement is non-negotiable - this is the minimum observation period to ensure the patient can maintain clinical stability on oral therapy alone before transitioning to outpatient care.